Report error Found 13 Enz. Inhib. hit(s) with Target = 'Epidermal growth factor receptor [1-770,'NPG',771-1210,T790M]'
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataEC50: <1nMAssay Description:Table B: The enzymatic assay used to determine activity was a Luminescence assay using a Microplate Reader ClarioStar Plus. The enzymatic reaction wa...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataEC50: 3nMAssay Description:Table B: The enzymatic assay used to determine activity was a Luminescence assay using a Microplate Reader ClarioStar Plus. The enzymatic reaction wa...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataEC50: 3nMAssay Description:Table B: The enzymatic assay used to determine activity was a Luminescence assay using a Microplate Reader ClarioStar Plus. The enzymatic reaction wa...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataEC50: 3nMAssay Description:Table B: The enzymatic assay used to determine activity was a Luminescence assay using a Microplate Reader ClarioStar Plus. The enzymatic reaction wa...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataEC50: 3nMAssay Description:Table B: The enzymatic assay used to determine activity was a Luminescence assay using a Microplate Reader ClarioStar Plus. The enzymatic reaction wa...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataIC50: 6.31nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataIC50: 7.27nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataIC50: 8.16nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataIC50: 8.80nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataIC50: 9.27nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataIC50: 11.4nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataIC50: 18.2nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210,T790M](Human)
Celyn Therapeutics
US Patent
Celyn Therapeutics
US Patent
Affinity DataIC50: 93.6nMAssay Description:The compound of the present invention had a good inhibitory activity on an EGFR kinase, and the IC50 values were all less than 10 μM. The specific ex...More data for this Ligand-Target Pair












